Dianthus Therapeutics Inc
NASDAQ:DNTH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Dianthus Therapeutics Inc
NASDAQ:DNTH
|
US |
|
K
|
Kirkland Lake Discoveries Corp
XTSX:KLDC
|
CA |
|
R
|
RH Bophelo Ltd
JSE:RHB
|
ZA |
|
Ares Acquisition Corporation II
NASDAQ:KDK
|
US |
|
Bastide le Confort Medical SA
PAR:BLC
|
FR |
|
P
|
Pato Chemical Industry PCL
SET:PATO
|
TH |
|
01 Communique Laboratory Inc
XTSX:ONE
|
CA |
|
Gaumont SA
PAR:GAM
|
FR |
|
Central Puerto SA
F:C3TA
|
AR |
|
T
|
Traphaco JSC
VN:TRA
|
VN |
|
Codere Online US Corp
NASDAQ:CDRO
|
MX |
|
S
|
Satra Properties (India) Ltd
BSE:508996
|
IN |
|
Smart Sand Inc
NASDAQ:SND
|
US |
|
A
|
argenx SE
F:1AE
|
NL |
|
T
|
Thai Metal Drum Manufacturing PCL
SET:TMD
|
TH |
|
Osmozis SA
PAR:ALOSM
|
FR |
|
F
|
FL Entertainment NV
AEX:FLE
|
FR |
|
F
|
Foodwell Corp
KOSDAQ:005670
|
KR |
Wall St Price Targets
DNTH Price Targets Summary
Dianthus Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for
DNTH is 142.14 USD with a low forecast of 123.22 USD and a high forecast of 210 USD.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is DNTH's stock price target?
Price Target
142.14
USD
According to Wall Street analysts, the average 1-year price target for
DNTH is 142.14 USD with a low forecast of 123.22 USD and a high forecast of 210 USD.
What is the Revenue forecast for Dianthus Therapeutics Inc?
Projected CAGR
143%
The compound annual growth rate for Revenue over the next 8 years is 143%.